Page 156 - ASHG 2013 Program Guide

POSTER SESSIONS
  143
POSTER SESSIONS
W=W
ednesday authors will present; T=Thursday authors will present; F=Friday authors will pr
esent
719
W Variants of the cysteinyl leukotriene 1 and 2
genes are additively associated with atopy in a founder
population.
M. Thompson, J. Stankova, V. Capra.
720
W Identification of exp ession quantitative trait
locus associated with drug biotransformation.
H.-C.
Yang, C.-W. Chen.
721
W Genome-wide association study of combined
paclitaxel and carboplatin treatment-induced severe
neutropenia/leucopenia for patients in Biobank Japan.
S. Low, S. Chung, A. Takahashi, T. Mushiroda, M. Kubo, Y.
Nakamura.
722
W Expression of
Mx1, OAS1, PKR
and
TP53
Interferon stimulated genes during treatment of
hepatitis C patients.
B. Swiatek, I. Bereszynska, D.
Januszkiewicz-Lewandowska, J. Wysocki, I. Mozer-
Lisewska, A. Kowala-Piaskowska, J. Rembowska, J.
Nowak.
723
W Analysis of the CYP3A4, CYP3A5, CYP2C9,
CYP2C19 and CYP2D6 polymorphism in Nayarit
population: Involvement in drug metabolism.
L. E.
Wong-Ley, A. B. Martinez Rizo, J. B. Velázquez Fernández,
V. Mondragón Jaimes, A. Y. Bueno Durán, A. Zambrano
Parra, F. J. Medrano Valenzuela.
724
W Can IL28B polymorphism identify patients who
achieve early virological response during treatment
of hepatitis C?
J. Nowak, B. Swiatek, J. Wysocki, I.
Bereszynska, A. Kowala-Piaskowska, I. Mozer-Lisewska,
J. Rembowska, D. Januszkiewicz-Lewandowska.
725
W Effect of genetically tailored statin therapy on
health behaviors and outcomes: A pilot study in the
primary care setting.
J. H. Li, S. V. Joy, S. B. Haga, L. A.
Orlando, W. E. Kraus, G. S. Ginsburg, D. Voora.
726
W Incidental pharmacogenetic variants identified
by massively parallel sequencing in the ClinSeq®
study.
D. Ng, J. J. Johnston, K. L. Lewis, S. G. Gonsalves,
W. Newman, P. D. Stenson, D. N. Cooper, M. Vemulapalli,
J. C. Mullikin, L. G. Biesecker, NIH Intramural Sequencing
Center.
727
W High throughput scaling and performance
assessment of gene panel capture with molecular
inversion probes.
L. S. Felker, A. Gordon, M. B. Beightol,
T. Shaffer, D. R. Crosslin, J. D. Smith, D. A. Nickerson.
728
W Pharmacogenetic genotyping of clinical
specimens using next-generation sequencing.
S. M.
Jacobs-Helber, T. Reynolds.
729
W Development of a scoring tool to prioritize
clinical pharmacogenomic testing.
S. Manzi, Clinical
Pharmacogenomics Oversight Committee.
730
W Assessment of the predictive effect of genetic
variation in key genes associated with drug therapy
of cardiovascular diseases in the Azores Islands
(
Portugal).
L. Mota-Vieira, M. S. Melo, L. Balanco, R.
Cabral, C. C. Branco, T. Pereirinha.
709
W PGRN network-wide project: Transcriptome
analysis of pharmacogenes in human tissues.
E. R.
Gamazon, C. E. French, S. W. Yee, A. Chhibber, X. Qin,
E. Theusch, A. Webb, A. Konkashbaev, S. Weiss, S. E.
Brenner, S. E. Scherer, N. J. Cox, K. M. Giacomini, on
behalf of PGRN RNASeq Group.
710
W Systematical functional characterization of
CYP2D6
alleles in the Chinese Han population.
S. Qin,
Q. Xu, Z. Wu, L. He.
711
W A pharmacogenomic study of inhaled
short-acting beta-agonist response in African
American individuals identifies
SPATA13-AS1
.
B.
Padhukasahasram, J. J. Yang, A. M. Levin, M. Yang, E. G.
Burchard, R. Kumar, P. Kwok, D. E. Lanfear, L. K. Williams.
712
W Genome-wide analysis of methotrexate
pharmacogenomics in rheumatoid arthritis reveals
novel risk variants and leads for
TYMS
regulation.
B.
K. Thelma, S. Senapati, S. Singh, M. Das, A. Kumar, R.
Gupta, U. Kumar, S. Jain, R. C. Juyal.
713
W Using neuroimaging endophenotypes to identify
molecular markers for treatment response to major
depressive disorder.
T. Carrillo-Roa, C. A. Lareau, C. L.
McGrath, B. W. Dunlop, M. E. Kelley, E. B. Binder, H. S.
Mayberg.
714
W Genome-wide association study loci are
enriched for clinically relevant drugs targets for
common human diseases.
R. Li, V. Forgetta, O. Yu, Z.
Dastani, M. Lathrop, J. B. Richards.
715
W Conditional analysis using
HLA-A*31:01
as a
covariant to detect additional genetic risk factors
for carbamazepine-induced cutaneous adverse
drug reactions in Japanese population.
T. Ozeki,
T. Mushiroda, A. Takahashi, M. Kubo, Y. Shirakata,
Z. Ikezawa, M. Iijima, T. Shiohara, K. Hashimoto, Y.
Nakamura.
716
W Whole genome association study identifies
novel antidepressant response loci for the treatment
of obsessive-compulsive disorder with selective
serotonin re-uptake inhibitors.
H. D. Qin, Y. Wang, M. A.
Grados, M. A. Riddle, B. D. Greenberg, J. A. Knowles, A.
J. Fyer, J. T. McCracken, D. L. Murphy, S. A. Rasmussen,
B. Cullen, J. Piacentini, D. Geller, D. Pauls, E. Stewart, O.
J. Bienvenu, Y. Chen, F. S. Goes, B. Maher, J. F. Samuels,
G. Nestadt, Y. Y. Shugart.
717
W Integrative genome modeling reveals common
genetic architecture of neuropathy resulting from
distinct environmental exposures.
H. E. Wheeler,
C. Wing, M. Komatsu, S. Delaney, E. R. Gamazon, C.
Rodriguez-Antona, N. J. Cox, M. E. Dolan.
718
W Genetic variants associated with elevated
triglyceride levels in patients with genotype 2/3 chronic
hepatitis C treated with cyclophilin inhibitor alisporivir.
Y. Li, M. Healey, M. Waldvogel, N. Hartmann, G. Nabel, L.
Li, F. Staedtler, W. Zhang, C. A. Brass, N. V. Naoumov, K.
J. Johnson, B. Li.